Objective: In this review, we aimed to discuss the efficacy of immunotherapy anti-programmed cell death protein 1 (PD-1) and programmed ligand (PD-L1) potential immune mechanism combination with various standard systemic therapies for breast cancer (BC) such as chemotherapy, targeted therapy, endocrine radiotherapy.